Ensuring Compliance for Pharma Companies Through Local Label Deviations

Drug delivery via the inhalation route is currently in demand for treatment of various diseases including asthma and chronic obstructive pulmonary disorders.

The aim of this webinar is to promote the fight against IP Crime in the area of Counterfeiting and Pharmaceutical Products.

Find out which market-moving events and catalysts to watch for during the upcoming Q1 Outlook Webinar - Key catalysts and their impact on pharma markets. During this webinar recording, industry analysts from Informa Pharma Intelligence present their data-based views on what’s in store for key drugs in early 2019. Discussion include important upcoming events related to these key drugs, their likelihood of phase/PDUFA review success and likelihood of approval, and an examination of the market significance of the drugs themselves.

Heritable disorders can often be linked back to a specific gene or genetic variant which transmits the risk of disease across generations. In most cases, the penetrance, or risk of being affected by the disease, for a pathogenic variant carrier is less than 100%. For an increasing number of disorders, the penetrance is even lower (20-50%), which begins to confound our ability to understand the relationship between disease risk and a specific genetic variant. At this level, classical tools, including family and functional studies, for assessment of variant pathogenicity loose power. This webinar will address the utility of the different lines of evidence in the classification of variants in moderate penetrance disease and recommended modifications to multivariate analysis in this setting.